CYSLTR1 and colorectal cancer: Inhibiting CysLT1 reduced both Wnt/β-catenin and PD-L1 expression, thus elucidating the importance of targeting CysLT1 to reach beneficial outcomes of immune checkpoint blockade in colorectal cancer patients [79].